Thumbnail - Request a copy

Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra)

Le Pen, Claude; Miadi-Fargier, Houda; Daures, JP.; Maurel, F.; Fautrel, B.; Maravic, M. (2008), Cost-effectiveness of using etanercept as first Line in severe and highly active rheumatoid Arthritis (ra), Value in Health, 11, 6, p. A541-A542. http://dx.doi.org/10.1016/S1098-3015(10)66787-3

Type
Article accepté pour publication ou publié
Date
2008
Journal name
Value in Health
Volume
11
Number
6
Publisher
Elsevier
Pages
A541-A542
Publication identifier
Metadata
Show full item record
Author(s)
Le Pen, Claude

Miadi-Fargier, Houda

Daures, JP.

Maurel, F.

Fautrel, B.

Maravic, M.
Subjects / Keywords
Drugs; Pharmaceutical industry; Health expenditures; Health care
JEL
I12 - Health Behavior
L65 - Chemicals; Rubber; Drugs; Biotechnology